Silent Stroke
11
4
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Stroke Prevention in Young Adults With Sickle Cell Anemia
Intraoperative Diagnosis of Neurocognitive Complications Via Electroencephalographic Analysis
Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions
Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions
Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion
Detection and Neurological Impact of Cerebrovascular Events in Cardiac Surgery Patients
Evaluation of Brain Damage Due to Coronary Angioplasty in Percutaneous Intervention Patients
Silent sTROke duriNG MitraClip Implantation
The Effectiveness and Cost Effectiveness of Intelligent Assessment of Gait Disorder in Silent Cerebrovascular Disease
Association Between Gait Assessed by Intelligent System and Cognitive Function in Silent Cerebrovascular Disease
Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO)